CANCER

Recommendations

Info

Bloodwise 26 STRATEGIC REPORT The opportunities in research to improve the lives of patients are unprecedented and we know that we could invest substantially more in high quality research. There is an urgent need to generate more income if we are to optimise the opportunity. We know that this is connected to poor awareness of blood cancers and the organisations that are here to help, and we also know that the majority of our income comes from people affected by blood cancers. The transactional nature of the name ‘Leukaemia & Lymphoma Research’ doesn’t convey the exciting movement of people that we are, and the opportunities that exist to be involved in beating blood cancer. Our partnership with Wickes now exceeds £4 million: FY15 was their biggest year ever, with Wickes customers and colleagues raising an incredible £1 million in just 12 months. Customers were able to buy red wheelbarrows and buckets throughout the year, with a proportion of profits going to their fundraising total. The August Bank Holiday weekend saw ‘Wickes Around the World’ take place: with exercise bikes in every store, colleagues cycled 32,000 miles – the equivalent of one and a half times around the world! Our awareness work later in the year will be a vital foundation to reaching more supporters and we know that we need to be more strategic and proactive with communication, engagement and relationship building. When we get this right, we create friends for life, but we need to be more systematic. Our new name, Bloodwise, will give us the opportunity to engage with new audiences, while nurturing and supporting the dedicated people who already support our work. We’ve restructured our larger gifts team to be better aligned to the needs of partners and supporters. Towards the end of the year we recruited an experienced Head of Major Funding, who is tasked with optimising the brand opportunity we now have. Via a project called ‘Knowing our Audiences’, which is analysing and understanding the motivations of our diverse supporter groups, we’ll be better placed to be more targeted with our innovation in fundraising – and able to respond to the needs of our supporters and the broader market. Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089 Registered charity 216032 (England & Wales) SC037529 (Scotland)
Bloodwise 27 STRATEGIC REPORT GOAL 3 Leverage resource through partnership Our partnership goal ensures that we work with others to help to optimise all of the resource that’s invested in beating blood cancers. We’ve rapidly developed from quite an introspective research charity into an organisation that uses our knowledge and resource for the benefit of patients in every way. Throughout this report there are very many examples of how by being at the heart of new partnerships we’re making more progress, more quickly. From our patient need research to the Trials Acceleration programme; to open access publishing to first in human trials – we share knowledge, talent and investment. Our first step is to deliver an authentically collaborative signposting service for patients, which reflects the 24 key needs we’ve uncovered and clearly points to the organisations and services that can help. Sharing the findings of our research with other charities including Leukaemia Care, the Lymphoma Association, Anthony Nolan, the Elimination of Leukaemia Fund, Delete Blood Cancer and Maggie’s has been a useful starting point to a more collaborative way to deliver for patients. Our research around the needs of patients, their families and health professionals has told us how important clear signposting services are. This has helped us start to think about our role in creating a more clearly defined sector for blood cancer patients. Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089 Registered charity 216032 (England & Wales) SC037529 (Scotland)
Page 1 and 2: Leukaemia & Lymphoma Research 1 Not
Page 3 and 4: Bloodwise 3 Report of the Trustees
Page 7 and 8: Bloodwise 7 STRATEGIC REPORT STRATE
Page 9 and 10: Bloodwise 9 STRATEGIC REPORT GOAL 1
Page 11 and 12: Bloodwise 11 STRATEGIC REPORT HIDIN
Page 13 and 14: Bloodwise 13 STRATEGIC REPORT FUELL
Page 15 and 16: Bloodwise 15 STRATEGIC REPORT Cradd
Page 17 and 18: Bloodwise 17 STRATEGIC REPORT RESEA
Page 19 and 20: Bloodwise 19 STRATEGIC REPORT 2. PR
Page 21 and 22: Bloodwise 21 STRATEGIC REPORT A VOI
Page 23 and 24: Bloodwise 23 STRATEGIC REPORT and n
Page 25: Bloodwise 25 STRATEGIC REPORT GOAL
Page 29 and 30: Bloodwise 29 STRATEGIC REPORT OUR S
Page 31 and 32: Bloodwise 31 STRATEGIC REPORT THE Y
Page 33 and 34: Bloodwise 33 STRATEGIC REPORT REGIO
Page 39 and 40: Bloodwise 39 STRATEGIC REPORT INVES
Page 41 and 42: Bloodwise 41 STRATEGIC REPORT In Fe
Page 43 and 44: Bloodwise 43 HOW WE HOW WORK WE Our
Page 45 and 46: Bloodwise 45 HOW WE WORK OUR APPLIC
Page 47 and 48: Bloodwise 47 STATEMENT OF TRUSTEE R
Page 49 and 50: Bloodwise 49 INDEPENDENT AUDITOR’
Page 51 and 52: Bloodwise 51 Group statement of fin
Page 53 and 54: Bloodwise 53 Group cash flow statem
Page 55 and 56: Bloodwise 55 Accounting policies fo
Page 57 and 58: Bloodwise 57 Notes to the Accounts

CANCER

Create successful ePaper yourself

Delete template?

Save as template?